Product Design, Manufacturing & Innovation Resources

Dernières publications et brevets en oncologie moléculaire

Publications en oncologie moléculaire Brevets

Astuce : suite à la sélection ci-dessous, vous pouvez rechercher et filtrer nos 2 bases de données complètes :

> outil de recherche de publications gratuit < par auteur, sujet, mots-clés, date ou revue.

> outil gratuit de recherche de brevets < pour les brevets en anglais de l'Office européen des brevets.

Oncologie moléculaire
Molecular oncology leverages advanced technologies to innovate cancer diagnosis and treatment through genetic and biochemical insights.

L'oncologie moléculaire étudie les altérations génétiques, épigénétiques et biochimiques à l'origine de l'initiation, de la progression et de la résistance aux traitements du cancer. Ce domaine intègre le séquençage à haut débit, le diagnostic moléculaire et les thérapies ciblées pour élucider les voies oncogéniques, l'inactivation des gènes suppresseurs de tumeurs et les interactions avec le microenvironnement tumoral. Les progrès en matière de profilage moléculaire, de découverte de biomarqueurs et de médecine de précision redéfinissent la classification du cancer et les stratégies thérapeutiques. Cette compilation présente les publications les plus récentes, évaluées par les pairs, ainsi que les innovations brevetées, reflétant la recherche de pointe sur les oncogènes, la transduction du signal, les cellules souches cancéreuses, l'immunomodulation et les techniques d'imagerie moléculaire essentielles à l'oncologie translationnelle et aux applications cliniques.

Il s'agit de notre dernière sélection de publications et de brevets mondiaux en anglais sur l'oncologie moléculaire, parmi de nombreuses revues scientifiques en ligne, classées et axées sur l'oncogène, la suppression des tumeurs, la voie de transduction des signaux, la génomique du cancer, l'épigénétique dans le cancer, le biomarqueur moléculaire, la thérapie ciblée du cancer, la signalisation cellulaire du cancer, la mutation de l'ADN, les microARN en oncologie, les cellules souches du cancer, la régulation de l'apoptose, microenvironnement tumoral, immunothérapie du cancer, profil d'expression génétique, aberration chromosomique, diagnostic moléculaire, protéomique du cancer, voie oncogène, métastase du cancer, mécanismes moléculaires de la cancérogenèse, hétérogénéité tumorale, épigénomique du cancer, virus oncogène, médicament moléculaire ciblé, transcriptomique du cancer, mécanisme de réparation de l'ADN, pharmacogénomique du cancer et pathologie moléculaire du cancer.

Lineage-loci engineered cell therapy and related methods of producing and using same

Patent published on the 2026-06-11 in WO under Ref WO2026123001 by UMOJA BIOPHARMA INC [US] (O'hara Samantha [us], Romanov Artem [us], Koning Ryan [us], Vereide David T [us], Yingst Ashley M [us], Jarrell Dillon [us])

Abstract: Provided herein are genetically engineered cells containing a payload in a lineage specific locus and related methods and uses thereof in cell therapy. In some embodiments, the cells are genetically engineered with a CAR, such that expression of the CAR is delayed until the cell is differentiated to a lineage. In some embodiments, the genetically modified cells can be selected for using a selection cassette. Also provided are cell compositions containing the engineered cells, and related methods[...]


Our summary: This content discusses lineage-loci engineered cell therapy and methods for producing genetically engineered cells. It highlights the use of CARs that are expressed upon cell differentiation. Additionally, it covers cell compositions, selection methods, and applications in cancer immunotherapy.

cell therapy, genetically engineered cells, CAR, lineage-specific locus

Patent

Tumor antigens for ovarian cancer and uses thereof

Patent published on the 2026-05-28 in WO under Ref WO2026107594 by UNIV DE MONTREAL [CA] (Perreault Claude [ca], Thibault Pierre [ca], Hardy Marie-pierre [ca], Vincent Krystel [ca])

Abstract: Ovarian cancer, notably high-grade serous ovarian cancer (HGSC), the principal cause of death from gynecological malignancies in the world, has not significantly benefited from recent progress in cancer immunotherapy. While HGSC infiltration by lymphocytes correlates with superior survival, the nature of antigens that can elicit anti-HGSC immune responses is still largely unknown. Novel tumor antigens shared by a large proportion of ovarian tumor cells are described herein. Several of the tumor [...]


Our summary: Novel tumor antigens for high-grade serous ovarian cancer are identified, derived from aberrantly expressed genomic sequences. These antigens are not present in normal tissues and may elicit immune responses. The study discusses their potential use in treatments, including nucleic acids, compositions, cells, and vaccines.

tumor antigens, ovarian cancer, immunotherapy, vaccines

Patent

Methods for predicting and improving the efficacy of car t-cell therapy

Patent published on the 2026-05-06 in EP under Ref EP4736874 by UNIV ZUERICH [CH] (Magnani Chiara Francesca [ch], Ponzo Marianna [ch], Gaipa Giuseppe [it], Biondi Andrea [it])

Abstract: [0001] Disclosed is a treatment with a combination of inhibitors useful to improve the effectiveness of CAR T-cell therapies by inhibiting hypoxia, VEGF pathways and inflammation at the tumor microenvironment, thereby enhancing the response to CAR T-cell therapy in tumor patients. There is also disclosed a method for predicting the response to CAR T-cell therapy by determining T cell surface expression markers.[...]


Our summary: The document discusses methods to enhance CAR T-cell therapy effectiveness through inhibitors targeting hypoxia, VEGF pathways, and inflammation. It also presents a predictive method for therapy response based on T cell surface expression markers. These approaches aim to improve patient outcomes in tumor treatments.

CAR T-cell therapy, efficacy prediction, tumor microenvironment, inhibitors

Patent

A fluid processing device for processing droplets

Patent published on the 2026-05-06 in EP under Ref EP4737004 by IMEC VZW [BE] (Yurt Abdulkadir [be], Set Ying Ting [be], Moloudi Reza [be], Vandevelde Bart [be])

Abstract: [0001] The present invention relates to a fluid processing device for processing droplets. The device comprises a plate-like structure comprising a plurality of functional pixels. Each functional pixel is adapted to perform multiple operations on a droplet located on the pixel. Specifically, each pixel can selectively carry out at least two of the following processing operations: manipulating the droplet (e.g., its position), applying heat to the droplet, and subjecting the droplet to a magnetic[...]


Our summary: The invention is a fluid processing device designed for droplet manipulation. It features a plate-like structure with functional pixels that can perform multiple operations on droplets. This device integrates various microfluidic functions into a compact platform for applications in biochemical analysis and drug discovery.

microfluidics, droplet manipulation, functional pixels, biochemical analysis

Patent

Combination of cancer vaccines and anti-trem2 agents for enhanced cancer immunotherapy

Patent published on the 2026-04-23 in WO under Ref WO2026085270 by UNIV TEXAS [US] (Gubin Matthew [us])

Abstract: The present disclosure generally relates to methods for treating cancer, and more specifically to combinatorial approaches using cancer vaccines together with agents targeting the TREM2 receptor to enhance anti-tumor immune responses. The invention includes methods of administering cancer vaccines in combination with anti-TREM2 agents. This approach enhances anti-tumor immunity by expanding tumor-specific T cells while reducing immunosuppressive macrophages in the tumor microenvironment. Additio[...]


Our summary: This disclosure presents methods for treating cancer using a combination of cancer vaccines and anti-TREM2 agents. The approach enhances anti-tumor immunity by increasing tumor-specific T cells and decreasing immunosuppressive macrophages. It also explores the combination of these agents with immune checkpoint inhibitors for improved therapeutic outcomes.

cancer vaccines, anti-TREM2 agents, immunotherapy, tumor microenvironment

Patent

Docking peptides and related antibody-based drug conjugates

Patent published on the 2026-04-23 in US under Ref US20260109780 by SONNET BIOTHERAPEUTICS INC [US] (Cini John K [us], Evans Nick [gb])

Abstract: [0000] Provided herein are novel docking peptides and antibody-based drug conjugates that include such docking peptides. In embodiments, the subject docking peptide allows for the controlled attachment of one or more drug moieties and a tumor targeting moiety that allows for the targeting of the drug moiety to the tumor microenvironment. [0000] In some embodiments, the antibody-based drug conjugates provided herein advantageously allows for enhanced targeted delivery of a drug payload having a c[...]


Our summary: Novel docking peptides enable controlled attachment of drug moieties for targeted delivery. Antibody-based drug conjugates enhance drug payload delivery to tumor sites. The technology allows for a controlled drug-to-antibody ratio for improved therapeutic efficacy.

docking peptides, antibody-drug conjugates, tumor targeting, drug delivery

Patent

Glioblastoma-Derived Extracellular Vesicles Modulate &gamma;&delta; T Lymphocytes Through a MIC-Dependent Mechanism

Published on 2026-02-03 by Micaela Rosato, Paula Saibene Vlez, Alejandra Infante Cruz, Matas A. Pibuel, Federico Fuentes, Mnica Vermeulen, Juan Iturrizaga, Pablo E. Espil, Silvia Berner, Gabriela V. Salamone, Carolina C. Jancic @MDPI

Abstract: Glioblastoma (GBM) is the most aggressive and common primary brain tumor, with a median survival of less than a year after diagnosis. &amp;gamma;&amp;delta; T lymphocytes are immune cells that can migrate to tumors and induce malignant cells&amp;rsquo; apoptosis. Our previous in silico studies showed that higher &amp;gamma;&amp;delta; T-cell infiltration in GBM correlates with better patient survival, and in vitro experiments showed that GMB supernatants promote an antitumora[...]


Our summary: Glioblastoma-derived extracellular vesicles (EVs) modulate gamma delta T lymphocytes through a MIC-dependent mechanism. Increased CD69 expression, cytotoxicity, and cytokine production in T cells were observed following EV interaction. These findings offer insights for targeted immunotherapy development in glioblastoma patients.

Extracellular vesicles, Glioblastoma, Gamma delta T lymphocytes, Immunotherapy

Publication

Dynamic microRNA Signatures as Biomarkers for Cardiac Ischemia and Remodeling

Published on 2026-02-03 by Macarena Rodrguez-Serrano, Elena Martn-Garca, Patricia Alonso-Andrs, Elisa Conde-Moreno, Hctor Pian, Javier del Moral-Salmoral, Nunzio Alcharani, Miriam Menacho-Romn, Lorena Crespo-Toro, Miren Edurne Ramos-Muoz, Carlos Zaragoza, Luis Miguel Rincn, Mara G. Barderas, Mara Laura Garca-Bermejo @MDPI

Abstract: Myocardial infarction (MI) triggers complex pathological processes, including inflammation, hypoxia, and fibrotic remodeling. MicroRNAs (miRNAs) have emerged as promising biomarkers for cardiovascular injury; however, their expression dynamics along processes remain underexplored. We used an in vivo rat model of permanent coronary occlusion to study the molecular alterations associated with MI and its resolution in a temporal mode, including five experimental groups with five animals in each: sh[...]


Our summary: This study investigates the dynamic expression of microRNAs as biomarkers for cardiac ischemia following myocardial infarction. Using a rat model, it identifies specific miRNAs that correlate with the progression and resolution of myocardial injury over time. The findings suggest that these miRNA signatures can serve as noninvasive indicators of cardiac stress and potential therapeutic targets.

microRNA, cardiac ischemia, biomarkers, myocardial infarction

Publication

Sujets abordés : Oncologie moléculaire, altérations génétiques, altérations épigénétiques, altérations biochimiques, séquençage à haut débit, diagnostics moléculaires, thérapeutiques ciblées, voies oncogéniques, gènes suppresseurs de tumeurs, microenvironnement tumoral, découverte de biomarqueurs, médecine de précision, classification des cancers, immunomodulation, imagerie moléculaire, oncologie translationnelle, applications cliniques, publications évaluées par les pairs, innovations brevetées ISO 15189, ISO 9001, ISO/IEC 17025, lignes directrices du CLSI et ASTM E2876.

Contexte historique

1965
1970
1980
1980
1990
1960
1969
1976-05-28
1980
1990

(si la date est inconnue ou non pertinente, par exemple « mécanique des fluides », une estimation arrondie de son émergence notable est fournie)

Les images en pleine résolution et les téléchargements sont uniquement disponibles, et 100% gratuits, pour les membres inscrits.